Pediatrix Medical Group (MD) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Pediatrix Medical Group published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Pediatrix Medical Group reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted EPS (non-GAAP), which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2025 GAAP EPS of $0.84 included a $20.9 million net gain on investments in divested businesses and a $7.0 million net discrete tax benefit, which is why GAAP EPS fell while Adjusted EPS rose.

Source: Pediatrix Medical Group Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Pediatrix Medical Group splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Pediatrix Medical Group's Net patient service revenue revenue was $434 million in Q3 2026, up 3% from $422 million in Q3 2025, 87% of total revenue.
• Pediatrix Medical Group's Hospital contract administrative fees revenue was $67.0 million in Q3 2026, down 1% from $67.7 million in Q3 2025, 13% of total revenue.
• Pediatrix Medical Group's Other revenue revenue was $0.7 million in Q3 2026, down 76% from $3.0 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Pediatrix Medical Group said:

“Pediatrix anticipates that its full year 2026 outlook for Adjusted EBITDA, as defined above, will be in a range of $290 million to $300 million.”

Source: Pediatrix Medical Group Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the MD forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenue and diluted net income per share, each as first reported in that quarter's release.

We do not hold a confirmed date for Pediatrix Medical Group's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Pediatrix Medical Group's Q3 2026 net revenue was $501.4 million, up $8.5 million or 1.7% from $492.9 million. Pediatrix is a physician services company whose roughly 4,300 affiliated physicians and other clinicians work in obstetrics, maternal-fetal medicine, neonatology and pediatric subspecialties, in hospitals and office-based practices. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026)

Most of Pediatrix's revenue is billed for patient care. Net patient service revenue was $433.7 million, hospital contract administrative fees $67.0 million and other revenue $0.7 million. Of net patient service revenue, contracted managed care paid about 72%, government payors 22%, other third parties 4% and private-pay patients 2%. (Pediatrix Medical Group Form 10-Q, Q3 2026, Oct 29, 2026)

Pediatrix splits growth into same-unit and non-same-unit pieces. Non-same-unit activity added 1.1 percent, driven by recent acquisitions and partly offset by practice dispositions, and same-unit revenue added 0.6 percent. Within same-unit revenue, reimbursement factors added 0.3 percent, from a favorable payor mix shift, higher administrative fees from hospital partners and higher patient acuity, mainly in neonatology; the share of services reimbursed by commercial and other non-government payors rose 70 basis points. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026)

Same-unit patient volume added 0.3 percent. Office-based patient services rose 2.9%, while hospital-based patient services fell 0.3% and neonatal intensive care unit (NICU) days fell 0.1%. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026)

Pediatrix Medical Group earned $0.59 per diluted share on a GAAP basis in Q3 2026, down from $0.84, while Adjusted EPS rose to $0.72 from $0.67. The year-ago GAAP figure included a $20.9 million net gain on investments in divested businesses ($0.18 per share after tax) and $7.0 million of net discrete tax benefits ($0.08 per share), both of which Adjusted EPS removes. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026)

Adjusted EPS also adds back amortization, stock-based compensation and transformational and restructuring expenses, the last worth $0.06 per share this quarter ($6.1 million before tax, mainly position eliminations and the revenue cycle management transition). The effective tax rate was 27.7%, against 18.3% a year earlier; excluding discrete items it was 27.2% and 26.8%. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026; Pediatrix Medical Group Form 10-Q, Q3 2026, Oct 29, 2026)

Weighted average diluted shares fell to 79.7 million from 85.6 million because of buybacks. Pediatrix spent $83.0 million on share repurchases in the quarter, and over the first nine months bought 5.9 million shares for $144.7 million under its $250.0 million program, leaving $21.5 million available. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026; Pediatrix Medical Group Form 10-Q, Q3 2026, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Pediatrix Medical Group guides on one figure, Adjusted EBITDA. In its Q3 2026 release it said it expects full-year 2026 Adjusted EBITDA of $290 million to $300 million, after $220.1 million in the first nine months. It does not give a revenue or EPS outlook. (Pediatrix Medical Group Q3 2026 release (EX-99.1), Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Pediatrix Medical Group, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Pediatrix Medical Group's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning MD is on is MD a buy or a sell?, what analysts expect next is on the MD forecast, and what the company does is on the Pediatrix Medical Group (MD) stock page.

Every number on this page can be traced to a document Pediatrix Medical Group published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.